BrainChild Bio develops CAR-T cell therapies for pediatric brain tumors, focusing on DIPG.
BrainChild Bio has raised $300K in total funding. The most recent round was Grant. The last funding was announced in January 2025.
BrainChild Bio's investors include ScaleReady.
BrainChild Bio is headquartered in Seattle, United States.
BrainChild Bio develops CAR-T cell therapies for pediatric brain tumors, focusing on DIPG.
BrainChild Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BrainChild Bio — Funding & Investors." VCBacked, January 21, 2025, https://www.vcbacked.co/company/brainchild-bio. Accessed August 13, 2026.
VCBacked. (2025). BrainChild Bio — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/brainchild-bio
{{cite web |title=BrainChild Bio — Funding & Investors |url=https://www.vcbacked.co/company/brainchild-bio |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated